August 9, 2024

Avidity Biosciences Announces Positive Data From Phase 1/2 EXPLORE44™ Trial of AOC 1044 in Individuals Amenable to Exon 44 Skipping

Avidity Biosciences, Inc. today announced positive data from the company’s Phase 1/2 EXPLORE44™ clinical trial of AOC 1044, an exon skipping therapy targeting those amenable to exon 44 skipping. Avidity also announced the approved international…

Learn More

February 13, 2023

Watch: Avidity Biosciences – EXPLORE44 Clinical Trial Investigating AOC 1044 – Webinar Recording

WATCH: Avidity Biosciences – EXPLORE44 Clinical Trial Investigating AOC 1044 in Individuals Amenable to Exon 44 Skipping Avidity Biosciences recently joined PPMD for a community webinar on February 8, 2023 to discuss the EXPLORE44™ clinical…

Learn More

September 27, 2022

Avidity Biosciences Announces FDA Clearance of IND Application for AOC 1044

PPMD is excited to share that Avidity Biosciences has announced that they have received clearance from the FDA on their Investigational New Drug (IND) application for AOC 1044, an exon skipping therapy targeting those amenable to exon…

Learn More